BMY
Neutral signalScored 2026-10-06 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Bristol-Myers Squibb Company
- Nom
- Bristol-Myers Squibb Company
- Secteur
- Healthcare
- Industrie
- Drug Manufacturers - General
- Bourse
- NYSE
- Capitalisation
- $125.6B
- Employés
- 32,500
- PDG
- Christopher Boerner
- Site web
- https://www.bms.com
- Marché
- ABBVAMGNAZNGILDGSKJNJ
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 6249 titres (~403498 USD)
- Insiders
- Massacesi Cristian
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$437,248
Avg sell (VWAP, 90d window) $64.79 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-09
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-09 | Massacesi Cristian | Sell · S | 6,249 | $64.57 | $403,498 | Form 4 |
| 2026-08-25 | Holzer Phil M | Sell · S | 500 | $67.50 | $33,750 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-05-07 | Mike Kelly | Sale (Full) | $15,001 - $50,000 |
| 2026-01-29 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2025-12-19 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-12-18 | Julie Johnson | Sale (Full) | $1,001 - $15,000 |
| 2025-11-13 | Julie Johnson | Sale (Partial) | $1,001 - $15,000 |
| 2025-11-12 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2025-10-09 | Gilbert Ray Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2025-09-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-09-05 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-08-14 | Julie Johnson | Sale (Partial) | $1,001 - $15,000 |
| 2025-06-24 | Virginia Ann Foxx | Sale (Full) | $1,001 - $15,000 |
| 2025-05-12 | Jefferson Shreve | Sale (Full) | $15,001 - $50,000 |
| 2025-04-28 | Julia Letlow | Sale (Full) | $1,001 - $15,000 |
| 2025-04-01 | Julie Johnson | Sale (Full) | $1,001 - $15,000 |
| 2025-03-27 | Greg Landsman | Sale (Full) | $1,001 - $15,000 |
| 2025-01-15 | Julie Johnson | Purchase | $1,001 - $15,000 |
| 2024-12-06 | Virginia Ann Foxx | Purchase | $1,001 - $15,000 |
| 2024-10-29 | Val Hoyle | Purchase | $1,001 - $15,000 |
| 2024-10-23 | Julia Letlow | Purchase | $1,001 - $15,000 |
| 2024-03-25 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2024-02-13 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2024-02-13 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-01-18 | John James | Sale (Full) | $1,001 - $15,000 |
| 2024-01-10 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2024-01-09 | Richard Ray Larsen | Sale (Full) | $1,001 - $15,000 |
| 2023-11-10 | John James | Purchase | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-24 | Greg Stanton | Sale (Full) | $1,001 - $15,000 |
| 2023-10-10 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-10-02 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-09-26 | Greg Stanton | Purchase | $1,001 - $15,000 |
| 2023-09-06 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-08-29 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-07-28 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-07-12 | Daniel Goldman | Sale (Full) | $15,001 - $50,000 |
| 2023-06-29 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-06-26 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-19 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2023-04-25 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-04-10 | Daniel Goldman | Purchase | $15,001 - $50,000 |
| 2023-04-10 | Daniel Goldman | Purchase | $50,001 - $100,000 |
| 2023-03-24 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-03-14 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2023-03-07 | Daniel Goldman | Sale (Full) | $1,001 - $15,000 |
| 2023-03-06 | Daniel Goldman | Sale (Partial) | $100,001 - $250,000 |
| 2023-02-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-01-25 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2023-01-25 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2023-01-25 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2023-01-11 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2022-11-28 | Van Taylor | Sale (Partial) | $100,001 - $250,000 |
| 2022-11-08 | Kurt Schrader | Sale (Full) | $1,001 - $15,000 |
| 2022-11-08 | Kurt Schrader | Purchase | $1,001 - $15,000 |
| 2022-07-15 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2022-04-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-04-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-03-16 | John Henry Rutherford | Sale (Full) | $1,001 - $15,000 |
| 2022-03-08 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-03-08 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-21 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2021-11-10 | Carol Devine Miller | Sale (Partial) | $15,001 - $50,000 |
| 2021-10-28 | Kim Schrier | Sale (Full) | $1,001 - $15,000 |
| 2021-09-23 | John Yarmuth | Purchase | $1,001 - $15,000 |
| 2021-09-22 | John Yarmuth | Purchase | $1,001 - $15,000 |
| 2021-06-07 | Thomas Suozzi | Sale (Partial) | $1,001 - $15,000 |
| 2021-06-07 | Thomas Suozzi | Sale (Full) | $1,001 - $15,000 |
| 2021-06-04 | Thomas Suozzi | Sale (Partial) | $1,001 - $15,000 |
| 2021-06-04 | Thomas Suozzi | Sale (Full) | $1,001 - $15,000 |
| 2021-02-05 | Kurt Schrader | Purchase | $1,001 - $15,000 |
| 2020-11-25 | Richard Ray Larsen | Purchase | $1,001 - $15,000 |
| 2020-11-19 | Kenny Marchant | Purchase | $15,001 - $50,000 |
| 2020-11-19 | Kenny Marchant | Purchase | $15,001 - $50,000 |
| 2020-10-22 | Katherine M. Clark | Sale (Full) | $1,001 - $15,000 |
| 2020-10-22 | George E.B. Holding | Sale (Full) | $1,001 - $15,000 |
| 2020-08-14 | George E.B. Holding | Sale (Full) | $1,001 - $15,000 |
| 2020-07-30 | Thomas Suozzi | Sale (Partial) | $1,001 - $15,000 |
| 2020-07-21 | John Henry Rutherford | Purchase | $1,001 - $15,000 |
| 2020-07-10 | Thomas Suozzi | Sale (Partial) | $1,001 - $15,000 |
| 2020-06-21 | John Henry Rutherford | Purchase | $1,001 - $15,000 |
| 2020-04-03 | Katherine M. Clark | Purchase | $1,001 - $15,000 |
| 2020-03-18 | Gilbert Ray Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2020-03-13 | Van Taylor | Sale (Full) | $100,001 - $250,000 |
| 2020-02-20 | Mikie Sherrill | Sale (Full) | $1,001 - $15,000 |
| 2020-01-21 | Mikie Sherrill | Purchase | $1,001 - $15,000 |
| 2020-01-14 | George E.B. Holding | Sale (Full) | $1,001 - $15,000 |
| 2020-01-14 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2020-01-09 | Thomas Suozzi | Sale (Full) | $15,001 - $50,000 |
| 2020-01-09 | Thomas Suozzi | Sale (Full) | $15,001 - $50,000 |
| 2020-01-09 | Thomas Suozzi | Purchase | $50,001 - $100,000 |
| 2019-12-18 | Mikie Sherrill | Sale (Full) | $1,001 - $15,000 |
| 2019-11-26 | Gilbert Ray Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2019-11-21 | Dean Phillips | Purchase | $1,001 - $15,000 |
| 2019-11-20 | Dean Phillips | Exchange | $1,001 - $15,000 |
| 2019-04-08 | Thomas Suozzi | Sale (Full) | $1,001 - $15,000 |
| 2019-04-08 | Thomas Suozzi | Sale (Full) | $15,001 - $50,000 |
| 2019-03-29 | Thomas Suozzi | Sale (Partial) | $1,001 - $15,000 |
| 2018-10-01 | Thomas Suozzi | Purchase | $15,001 - $50,000 |
| 2018-04-17 | Thomas Suozzi | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-06 Drivers: fundamentals. Moteurs : fondamentaux.
BMY shows genuine financial recovery in 2025 with improved margins and deleveraging, but the catalyst score of 20 with no identifiable event-driven trigger severely limits near-term upside potential.
The first sentence of the analysis written for BMY on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 1.26 · operating margin 28%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 71.1% | 56.8% | 56.3% | 57.4% | 57.7% | |
| Ebit Margin | 23.3% | -13.3% | 21.3% | 19.4% | 20.3% | |
| Ebitda Margin | 31.6% | 6.6% | 43.0% | 41.6% | 43.4% | |
| Operating Profit Margin | 28.5% | 20.0% | 18.8% | 20.1% | 20.6% | |
| Pretax Profit Margin | 19.4% | -17.3% | 18.8% | 16.7% | 17.5% | |
| Continuous Operations Profit Margin | 14.6% | -18.5% | 17.9% | 13.7% | 15.1% | |
| Net Profit Margin | 14.6% | -18.5% | 17.8% | 13.7% | 15.1% | |
| Bottom Line Profit Margin | 14.6% | -18.5% | 17.8% | 13.7% | 15.1% | |
| Current Ratio | 1.255 | 1.253 | 1.427 | 1.246 | 1.521 | |
| Quick Ratio | 1.140 | 1.145 | 1.308 | 1.139 | 1.425 | |
| Solvency Ratio | 0.155 | 0.009 | 0.271 | 0.253 | 0.241 | |
| Cash Ratio | 0.436 | 0.435 | 0.515 | 0.417 | 0.639 | |
| Price To Earnings Ratio | 15.590 | -12.825 | 13.224 | 24.226 | 19.794 | |
| Price To Earnings Growth Ratio | -0.087 | 0.060 | 0.432 | -4.239 | -0.110 | |
| Forward Price To Earnings Growth Ratio | -0.087 | 0.060 | 0.432 | -4.239 | -0.110 | |
| Price To Earnings Diluted Ratio | 15.635 | -12.825 | 13.293 | 24.390 | 19.984 | |
| Price To Earnings Diluted Growth Ratio | -0.088 | 0.060 | 0.431 | -4.476 | -0.112 | |
| Price To Book Ratio | 5.960 | 7.018 | 3.607 | 4.934 | 3.852 | |
| Price To Sales Ratio | 2.284 | 2.374 | 2.359 | 3.320 | 2.985 | |
| Price To Free Cash Flow Ratio | 8.571 | 8.223 | 8.391 | 12.827 | 9.090 | |
| Price To Operating Cash Flow Ratio | 7.777 | 7.548 | 7.659 | 11.729 | 8.544 | |
| Debt To Assets Ratio | 0.524 | 0.553 | 0.436 | 0.421 | 0.417 | |
| Debt To Equity Ratio | 2.552 | 3.134 | 1.409 | 1.311 | 1.268 | |
| Debt To Capital Ratio | 0.718 | 0.758 | 0.585 | 0.567 | 0.559 | |
| Long Term Debt To Capital Ratio | 0.699 | 0.745 | 0.555 | 0.530 | 0.524 | |
| Financial Leverage Ratio | 4.874 | 5.669 | 3.233 | 3.117 | 3.041 | |
| Working Capital Turnover Ratio | 8.047 | 6.227 | 6.045 | 5.503 | 4.122 | |
| Operating Cash Flow Ratio | 0.605 | 0.639 | 0.623 | 0.597 | 0.741 | |
| Operating Cash Flow Sales Ratio | 0.294 | 0.314 | 0.308 | 0.283 | 0.349 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.907 | 0.918 | 0.913 | 0.914 | 0.940 | |
| Debt Service Coverage Ratio | 3.121 | 0.655 | 4.426 | 3.248 | 3.030 | |
| Interest Coverage Ratio | 7.258 | 4.960 | 7.266 | 7.525 | 7.151 | |
| Short Term Operating Cash Flow Coverage Ratio | 6.261 | 7.424 | 4.444 | 3.064 | 3.275 | |
| Operating Cash Flow Coverage Ratio | 0.300 | 0.297 | 0.334 | 0.321 | 0.355 | |
| Capital Expenditure Coverage Ratio | 10.798 | 12.171 | 11.464 | 11.687 | 16.657 | |
| Dividend Paid And Capex Coverage Ratio | 2.227 | 2.486 | 2.328 | 2.272 | 3.019 | |
| Dividend Payout Ratio | 0.715 | -0.543 | 0.591 | 0.732 | 0.629 | |
| Enterprise Value Multiple | 9.653 | 49.085 | 7.031 | 9.617 | 8.455 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 71.1% | ▲14.3% | ▲11.2% |
| Ebit Margin | 23.3% | ▲36.6% | ▲9.1% |
| Ebitda Margin | 31.6% | ▲25.0% | ▼-1.6% |
| Operating Profit Margin | 28.5% | ▲8.5% | ▲6.9% |
| Pretax Profit Margin | 19.4% | ▲36.7% | ▲8.4% |
| Continuous Operations Profit Margin | 14.6% | ▲33.1% | ▲6.1% |
| Net Profit Margin | 14.6% | ▲33.2% | ▲6.1% |
| Bottom Line Profit Margin | 14.6% | ▲33.2% | ▲6.1% |
| Current Ratio | 1.255 | ▲0.002 | ▼-0.085 |
| Quick Ratio | 1.140 | ▼-0.005 | ▼-0.091 |
| Solvency Ratio | 0.155 | ▲0.146 | ▼-0.031 |
| Cash Ratio | 0.436 | ▲0.001 | ▼-0.052 |
| Price To Earnings Ratio | 15.590 | ▲28.415 | ▲3.588 |
| Price To Earnings Growth Ratio | -0.087 | ▼-0.147 | ▲0.702 |
| Forward Price To Earnings Growth Ratio | -0.087 | ▼-0.147 | ▲0.702 |
| Price To Earnings Diluted Ratio | 15.635 | ▲28.460 | ▲3.540 |
| Price To Earnings Diluted Growth Ratio | -0.088 | ▼-0.148 | ▲0.749 |
| Price To Book Ratio | 5.960 | ▼-1.059 | ▲0.885 |
| Price To Sales Ratio | 2.284 | ▼-0.089 | ▼-0.380 |
| Price To Free Cash Flow Ratio | 8.571 | ▲0.348 | ▼-0.850 |
| Price To Operating Cash Flow Ratio | 7.777 | ▲0.230 | ▼-0.875 |
| Debt To Assets Ratio | 0.523 | ▼-0.029 | ▲0.054 |
| Debt To Equity Ratio | 2.552 | ▼-0.583 | ▲0.617 |
| Debt To Capital Ratio | 0.719 | ▼-0.040 | ▲0.081 |
| Long Term Debt To Capital Ratio | 0.699 | ▼-0.046 | ▲0.088 |
| Financial Leverage Ratio | 4.874 | ▼-0.795 | ▲0.887 |
| Working Capital Turnover Ratio | 8.047 | ▲1.820 | ▲2.058 |
| Operating Cash Flow Ratio | 0.605 | ▼-0.034 | ▼-0.036 |
| Operating Cash Flow Sales Ratio | 0.294 | ▼-0.021 | ▼-0.016 |
| Free Cash Flow Operating Cash Flow Ratio | 0.907 | ▼-0.011 | ▼-0.011 |
| Debt Service Coverage Ratio | 3.121 | ▲2.466 | ▲0.225 |
| Interest Coverage Ratio | 7.258 | ▲2.297 | ▲0.425 |
| Short Term Operating Cash Flow Coverage Ratio | 6.261 | ▼-1.163 | ▲1.367 |
| Operating Cash Flow Coverage Ratio | 0.300 | ▲0.004 | ▼-0.021 |
| Capital Expenditure Coverage Ratio | 10.798 | ▼-1.374 | ▼-1.758 |
| Dividend Paid And Capex Coverage Ratio | 2.227 | ▼-0.259 | ▼-0.239 |
| Dividend Payout Ratio | 0.715 | ▲1.259 | ▲0.290 |
| Enterprise Value Multiple | 9.653 | ▼-39.431 | ▼-7.115 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $110.09B | $114.65B | $106.16B | $153.25B | $138.48B | |
| Enterprise value | $147.02B | $155.50B | $136.16B | $184.85B | $170.10B | |
| EV / Sales | 3.05x | 3.22x | 3.02x | 4.00x | 3.67x | |
| EV / Op. cash flow | 10.39x | 10.24x | 9.82x | 14.15x | 10.49x | |
| EV / Free cash flow | 11.45x | 11.15x | 10.76x | 15.47x | 11.17x | |
| EV / EBITDA | 9.65x | 49.09x | 7.03x | 9.62x | 8.46x | |
| Net debt / EBITDA | 2.42x | 12.90x | 1.55x | 1.64x | 1.57x | |
| Current ratio | 1.25x | 1.25x | 1.43x | 1.25x | 1.52x | |
| Income quality | 2.01x | -1.70x | 1.72x | 2.06x | 2.31x | |
| Graham number | $27 | — | $35 | $31 | $34 | |
| Graham net-net | -$24 | -$26 | -$20 | -$21 | -$21 | |
| Tax burden | 75.6% | 106.8% | 95.1% | 82.0% | 86.4% | |
| Interest burden | 83.1% | 130.3% | 87.9% | 86.2% | 85.9% | |
| Working capital | $5.97B | $6.01B | $9.51B | $5.38B | $11.39B | |
| Invested capital | $55.95B | $59.73B | $66.20B | $70.36B | $81.64B | |
| Return on assets | 7.8% | -9.7% | 8.4% | 6.5% | 6.4% | |
| Operating ROA | 15.0% | 10.3% | 8.8% | 9.0% | 8.4% | |
| Return on tangible assets | 14.3% | -18.9% | 17.3% | 16.1% | 15.2% | |
| Return on equity | 38.2% | -54.8% | 27.3% | 20.4% | 19.5% | |
| Return on invested capital | 15.0% | 13.6% | 10.6% | 9.6% | 8.9% | |
| Return on capital employed | 20.6% | 14.0% | 11.6% | 12.4% | 10.9% | |
| Earnings yield | 6.4% | -7.8% | 7.6% | 4.1% | 5.1% | |
| Free cash flow yield | 11.7% | 12.2% | 11.9% | 7.8% | 11.0% | |
| Capex / Op. cash flow | 9.3% | 8.2% | 8.7% | 8.6% | 6.0% | |
| Capex / Depreciation | 32.7% | 13.0% | 12.4% | 10.9% | 9.1% | |
| Capex / Sales | 2.7% | 2.6% | 2.7% | 2.4% | 2.1% | |
| SG&A / Sales | 15.1% | 16.3% | 17.1% | 16.9% | 16.6% | |
| R&D / Sales | 20.6% | 20.3% | 20.5% | 20.4% | 20.6% | |
| Stock comp / Sales | 1.1% | 1.0% | 1.2% | 1.0% | 1.3% | |
| Intangibles / Total assets | 45.4% | 49.0% | 51.1% | 59.4% | 57.9% | |
| Days sales outstanding | 110d | 109d | 124d | 110d | 98d | |
| Days payables outstanding | 94d | 63d | 61d | 56d | 55d | |
| Operating cycle | 180d | 154d | 173d | 154d | 137d | |
| Cash conversion cycle | 87d | 91d | 113d | 97d | 83d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-05 BMY or ARGX: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Bristol Myers Squibb (BMY) or argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?
- 2026-10-05 Are Investors Undervaluing Bristol Myers Squibb (BMY) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
- 2026-10-05 3 Stocks With Broker Rating Upgrades Amid Resilient Equity Markets Dollar General, Bristol-Myers and Equinor stand out after broker rating upgrades, backed by projected earnings growth and resilient U.S. equity markets.
- 2026-10-04 3 Dirt Cheap Dividend Stocks Worth Buying in October There are blazing deals for some of the top healthcare stocks -- companies with proven track records and dividend yields as high as 6%.
- 2026-10-03 Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy? Bristol Myers has faced patent cliffs in recent years, and there are more on the horizon. The company seems relatively well equipped to deal with this issue moving forward.
- 2026-10-02 Will Camzyos Growth Keep Driving BMY''s Cardiovascular Portfolio? Bristol Myers'' Camzyos gains a broader FDA label and strong sales growth, while emerging competitors and pipeline setbacks shape its cardiovascular outlook.
- 2026-10-01 AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? AbbVie continues to grow its revenue base by successfully transitioning from Humira to its next-generation immunology drugs. Bristol Myers Squibb maintains high net margins and offers a significant valuation discount compared to its peer.
- 2026-10-01 Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale Johnson & Johnson generates consistently higher quarterly revenue than Bristol-Myers Squibb, maintaining a clear lead in total dollars over the entire observed eight-quarter period without any interruption. Both companies experienced a gentle pattern of quarter-over-quarter revenue growth over the last two calendar years, though the exact quarterly figures occasionally fluctuated between consecutive reporting periods.
- 2026-10-01 5 High-Yield Dividends With Ex-Dates Days Away: Buy Before the Window Closes Four dividend stocks from Philip Morris to JPMorgan Chase have ex-dates landing within days, and missing the cutoff means the payout goes to the seller. The clock is already running.
- 2026-10-01 Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement.